
Sign up to save your podcasts
Or


Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
By JAMA Network3.8
1111 ratings
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

320 Listeners

496 Listeners

40 Listeners

163 Listeners

57 Listeners

112,586 Listeners

38 Listeners

56,435 Listeners

21 Listeners

12 Listeners

8 Listeners

16 Listeners

18 Listeners

5 Listeners

6 Listeners

44 Listeners

29 Listeners

9 Listeners

90 Listeners

14 Listeners

5 Listeners

5 Listeners

106 Listeners

19 Listeners

14,589 Listeners

3 Listeners

1,227 Listeners